Business Wire

Regula Repeatedly Named a Representative Vendor in Gartner Market Guide for Identity Verification

14.9.2023 10:00:00 EEST | Business Wire | Press release

Share

The identity verification industry has evolved significantly in recent years, expanding its scope beyond traditional Know Your Customer (KYC) processes. As IDV is becoming the new norm, more identity verification providers are vying for the attention of potential customers.

While the market is becoming a buyer’s market, it can also be confusing because of the many seemingly similar offers. As Gartner notes, “It is challenging for end-user organizations to select a vendor in a crowded market. Many tend to simply select vendors with experience and presence in their country or region.” However, it’s more important than ever before to have comprehensive selection criteria when choosing a solution.

The two pillars of identity verification: Document authenticity and liveness check

In the era of digital nomadism, it’s an advantage for a vendor to have global coverage of supported IDs. Not only is it a plus for user experience, but it also provides qualitative attributes for effective fraud prevention.

Also, remote interactions are paramount in most scenarios. A proper solution should offer an extensive set of document verification checks, from automatic document type recognition to NFC-based verification (the most trustworthy method). Concerning the latter, an effective solution should allow re-verification of electronic chips by processing results on a server, thus eliminating the risk of accepting a tampered ID.

As for binding the ID to the actual individual, it may already be not enough to ask users to take selfies (passive liveness check). Organizations need to be able to detect various biometric fraud, including injection attacks, and be able to compare live biometrics with the photo on the document and the data encoded in the chip embedded in the ID.

All in all, it’s crucial for a vendor to deliver a complete verification solution that tackles everything mentioned above. These key tasks are covered by Regula’s products acknowledged in the report—Regula Document Reader SDK and Regula Face SDK. Together, they form a solid future-proof foundation for reliable identity verification.

Beyond the basics

Given the evolving landscape of security challenges and the growing demand for comprehensive solutions, organizations are looking for tools that can offer more than just the basics. Vendors are expected to stand out by adding more value through augmenting core capabilities with novel implementation approaches and the ability to handle AI-enabled attack vectors.

According to Regula’s latest survey, in the past year, 37% of organizations encountered incidents of deepfake voice fraud, while 29% fell victim to deepfake videos. The increasing accessibility of artificial intelligence technology for crafting deepfakes is amplifying these risks, posing a significant challenge for both businesses and individuals.

Regula has taken a proactive approach to fortifying defenses against this threat by investing in a forward-looking roadmap. "When it comes to detecting deepfakes, we believe that neural networks can be valuable for defensive purposes, as long as they come with other anti-fraud measures that focus on physical and dynamic parameters,” says Henry Patishman, VP of Identity Verification Solutions at Regula. “These include face liveness checks, document liveness checks, optically variable security elements, and more. It's still challenging to create deepfakes that show the expected dynamic behavior. Verifying the liveness of an object can provide a crucial advantage against fraudsters. Additionally, cross-referencing user information with biometric checks and recent transaction history can enhance the verification process."

*Gartner, Market Guide for Identity Verification, Akif Khan, 7 September 2023

About Gartner

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Proofing and Affirmation in 2022. Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristina – ks@regulaforensics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye